BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, yesterday hosted the U.S. Department of Commerce Invest in America event sponsored by the Greater Phoenix Economic Council at InNexus’ facilities located on the Campus of Mayo Clinic in Scottsdale, Arizona. The event highlighted the importance of Foreign Direct Investment for jobs and economic growth through a series of site visits to foreign investor-owned facilities in States across the USA.
